- new May 21, 2025
Public Law 2023, Chapter 610 (LD 2282, An Act to Provide Greater Transparency About the Cost of Insulin and to Promote the Availability of Low-cost Insulin in the State) requires a manufacturer of insulin to report to the Maine Health Data Organization no later than February 15th of each year the wholesale acquisition cost per pricing unit for the insulin produced by the manufacturer in each category of insulin. The reporting requirements are defined in 90 590 C.M.R. Ch. 800, Uniform Reporting of the Cost of Insulin. Chapter 800 is a major substantive rule recently enacted (LD 729) as an emergency measure by the Maine Legislature and signed by Governor Mills on March 25, 2025. The MHDO board of directors met in April 2025 and voted unanimously on the final adoption of Ch. 800. The chapter became effective May 15, 2025.
The first round of reporting the cost of insulin as defined in Ch. 800, is due to MHDO by February 15, 2026.
A step by step demonstration of how to submit insulin wholesale acquisition costs data via the MHDO Prescription Drug Price Data Portal is available on YouTube here: https://youtu.be/5744Nl_Ajy4.
Please note the following definitions below for the different categories of insulin: